Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic
conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical
trial.
Author(s): Carr WW(1), Nayak AS, Ratner PH, Gow JA, McNamara TR, Williams JI; Bepotastine
Besilate Ophthalmic Solution 1.5% (Bepreve) Study Group.
Collaborators: Berman G, Bernstein D, Carr W, Gower R, Hampel F Jr, Henderson D,
Nayak A, Posner L, Ratner P, Saff R, Stillerman A, Wald J.
Affiliation(s): Author information:
(1)Allergy and Asthma Association of Southern California, Mission Viejo, CA, USA.
Publication date & source: 2013, Allergy Asthma Proc. , 34(3):247-54
Allergic conjunctivitis (AC) affects an estimated 20% of the population in the
Western world, with a large fraction suffering due to seasonal or perennial
allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a
dual-acting histamine (H(1)) receptor antagonist and mast cell stabilizer, is
indicated for itching associated with AC. This study was designed to evaluate the
efficacy and safety of BBOS 1.5% for reducing ocular itching associated with AC
in subjects enrolled in a natural exposure trial. Eligible subjects in a
multicenter, double-masked, randomized, parallel-group, placebo-controlled,
natural exposure clinical trial were randomly assigned to either BBOS 1.5% or
placebo eyedrops on a 1:1 basis and instilled 1 drop of the test agent into both
eyes twice daily for 2 weeks. The mean change from baseline in instantaneous and
reflective ocular itching scores at the end of 2 weeks of treatment were
evaluated based on subject-assessed severity of instantaneous and reflective
itching. Subject-reported adverse events (AEs) were also recorded for safety.
Treatment with BBOS 1.5% significantly reduced instantaneous and reflective
ocular itching scores from baseline compared with placebo over the 2-week study
period(p = 0.007 and p = 0.005, respectively). BBOS 1.5% was well tolerated, and
AEs were generally transient and mild. This clinical study indicates BBOS 1.5%
effectively and safely treated ocular itching in a natural exposure allergy study
and is a useful treatment option for the management of ocular itching associated
with AC. (ClinicalTrials.gov identifier number: NCT01174823.)
|